Photoimmunotherapy for gastrointestinal cancer
Project/Area Number |
25462021
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Digestive surgery
|
Research Institution | Okayama University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
KAGAWA Shunsuke 岡山大学, 大学病院, 准教授 (00362971)
OYAMA Takanori 岡山大学, 大学病院, 助教 (10380164)
|
Co-Investigator(Renkei-kenkyūsha) |
FUJIWARA Toshiyoshi 岡山大学, 大学院医歯薬学総合研究科, 教授 (00304303)
TAZAWA Hiroshi 岡山大学, 大学病院, 助教 (90415513)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 光免疫療法 / HER2 / 腹膜播種 / アデノウイルス / 胃癌 / 近赤外線光線免疫療法 / 消化器癌 / 近赤外光線免疫療法 |
Outline of Final Research Achievements |
The lack of particular target antigens in gastric cancer other than HER2 has hampered the development of new treatments for gastric cancer.We hypothesized that HER2-extracellular domain (HER2-ECD) gene transduction combined with trastuzumab-based photoimmunotherapy (PIT) might provide excellent and selective antitumor effects for peritoneal dissemination of gastric cancer. Adenovirus/HER2-ECD(Ad/HER2-ECD) efficiently transduced HER2-ECD into HER2-negative gastric cancer cells. Trastuzumab-mediated PIT induced selective cell death of HER2-ECD-transduced tumor cells, even in heterogeneous gastric cancer cells.Anti-HER2 PIT integrated with adenoviral HER2-ECD gene transfer was applied in mice bearing peritoneal dissemination of HER2-negative gastric cancer. Intraperitoneal administration of Ad/HER2-ECD and Tra-IR700 with PIT inhibited peritoneal metastasis and prolonged the survival of mice. Molecular-targeted PIT integrated with gene transfer technology is a promising strategy.
|
Report
(4 results)
Research Products
(15 results)
-
-
-
-
[Journal Article] Viral transduction of the HER2-extracellular domain expands trastuzumab-based photoimmunotherapy for HER2-negative breast cancer cells2015
Author(s)
Shimoyama K, Kagawa S, Ishida M, Watanabe S, Noma K, Takehara K, Tazawa H, Hashimoto Y, Tanabe S, Matsuoka J, Kobayashi H, Fujiwara T
-
Journal Title
Breast Cancer Reseach and Treatment
Volume: 149
Issue: 3
Pages: 597-605
DOI
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
[Journal Article] A genetically engineered oncolytic adenovirus decoys and lethally traps quiescent cancer stem-like cells into S/G2/M-phases.2013
Author(s)
Yano S, Tazawa H, Hashimoto Y, Shirakawa Y, Kuroda S, Nishizaki M, Kishimoto H, Uno F, Nagasaka T, Urata Y, Kagawa S, Hoffman RM, Fujiwara T
-
Journal Title
Clin Cancer Res
Volume: 19
Issue: 23
Pages: 6495-6505
DOI
Related Report
Peer Reviewed
-
-
-
-
[Presentation] HER2抗原で修飾された癌細胞に対するTrastuzumabを用いた近赤外線光線免疫療法の効果2014
Author(s)
石田道拡, 香川俊輔, 下山京子, 竹原清人, 野間和広, 田澤 大, 黒田新士, 岸本浩行, 田邊俊介, 小林久隆, 藤原俊義
Organizer
第73回日本癌学会学術総会
Place of Presentation
神奈川県横浜市
Year and Date
2014-09-25
Related Report
-
-
-
-
-